Imbalanced Kynurenine Pathway in Schizophrenia

International Journal of Tryptophan Research

Volumn 7, Issue , 2014, Pages 15-22

  Kegel, Magdalena E ^a   Bhat, Maria ^a,b   Skogh, Elisabeth ^c   Samuelsson, Martin ^c   Lundberg, Kristina ^c   Dahl, Marja Liisa ^d   Sellgren, Carl ^a   Schwieler, Lilly ^a   Engberg, Göran ^a   Schuppe Koistinen, Ina ^a,b   Erhardt, Sophie ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SCIENCE FOR LIFE LABORATORY   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cerebrospinal fluid; Inflammation; Kynurenic acid; NMDA receptor; Psychosis; Quinolinic acid

Indexed keywords

EID: 84926392720     PISSN: None     EISSN: 11786469     Source Type: Journal    
DOI: 10.4137/IJTR.S16800     Document Type: Article

References (43)

1. Erhardt S, Olsson SK, Engberg G. Pharmacological manipulation of kynurenic acid -potential in the treatment of psychiatric disorders. CNS Drugs. 2009;23(2):91-101.
2. Schwarcz R, Bruno JP, Muchowski PJ, Wu H-Q. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 2012;13(7):465-77.
3. Erhardt S, Blennow K, Nordin C, Skogh E, Lindström LH, Engberg G. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett. 2001;313(1-2):96-8.
4. Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC. Increased cortical kynurenate content in schizophrenia. Biol Psychiatry. 2001;50(7):521-30.
5. Olsson S. Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder. J Psychiatry Neurosci. 2010;35(3):195-9.
6. Linderholm KR, Skogh E, Olsson SK, et al. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull. 2012;38(3):426-32.
7. Sathyasaikumar KV, Stachowski EK, Wonodi I, et al. Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr Bull. 2011;37(6):1147-56.
8. Lavebratt C, Olsson S, Backlund L, et al. The KMO allele encoding Arg(452) is associated with psychotic features in bipolar disorder type 1, and with increased CSF KYNA level and reduced KMO expression. Mol Psychiatry. 2014;19(3):334-41.
9. Wonodi I, Stine OC, Sathyasaikumar KV, et al. Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Arch Gen Psychiatry. 2011;68(7):665-74.
10. Miller CL, Llenos IC, Dulay JR, Weis S. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res. 2006;107(3-1074): 25-37.
11. Stone TW. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev. 1993;45(3):309-79.
12. Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci. 2001;21(19):7463-73.
13. Erhardt S, Schwieler L, Emanuelsson C, Geyer M. Endogenous kynurenic acid disrupts prepulse inhibition. Biol Psychiatry. 2004;56(4):255-60.
14. Pocivavsek A, Wu H-Q, Elmer GI, Bruno JP, Schwarcz R. Pre-and postnatal exposure to kynurenine causes cognitive deficits in adulthood. Eur J Neurosci. 2012;35(10):1605-12.
15. Chess AC, Bucci DJ. Increased concentration of cerebral kynurenic acid alters stimulus processing and conditioned responding. Behav Brain Res. 2006;170(2): 326-32.
16. Potter MC, Elmer GI, Bergeron R, et al. Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. Neuropsychopharmacology. 2010;35(8):1734-42.
17. Chess AC, Simoni MK, Alling TE, Bucci DJ. Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr Bull. 2007;33(3): 797-804.
18. Olsson SK, Larsson MK, Erhardt S. Subchronic elevation of brain kynurenic acid augments amphetamine-induced locomotor response in mice. J Neural Transm. 2012;119(2):155-63.
19. Guillemin GJ. Quinolinic acid, the inescapable neurotoxin. FEBS J. 2012;279(8):1356-65.
20. Guidetti P, Luthi-Carter RE, Augood SJ, Schwarcz R. Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol Dis. 2004;17(3):455-61.
21. Guillemin GJ, Smythe G, Takikawa O, Brew BJ. Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia. 2005;49(1):15-23.
22. Erhardt S, Lim CK, Linderholm KR, Janelidze S, Lindqvist D, Guillemin GJ. Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacology. 2013;38:743-52.
23. Steiner J, Walter M, Gos T, et al. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J Neuroinflammation. 2011;8:94.
24. Campbell BM, Charych E, Lee AW, Möller T. Kynurenines in CNS disease: regulation by inflammatory cytokines. Front Neurosci. 2014;8:12.
25. Mándi Y, Vécsei L. The kynurenine system and immunoregulation. J Neural Transm. 2012;119(2):197-209.
26. Kegel ME, Svensson CI, Erhardt S. IL-1 induces IDO and TDO transcription and provokes the release of kynurenic acid from human astrocytes in vitro. Progr No 24019/E7 Neurosci Meet Planner Washington, DC Soc Neurosci Online. 2011.
27. Schwarcz R, Tamminga CA, Kurlan R, Shoulson I. Cerebrospinal fluid levels of quinolinic acid in Huntington's disease and schizophrenia. Ann Neurol. 1988;24(4):580-2.
28. American Psychiatric Association X. Diagnostic and Statistical Manual of Mental Disorders. Fourth. Washington, DC: American Psychiatric Association; 1994.
29. Skogh E, Sjödin I, Josefsson M, Dahl M-L. High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug. J Clin Psychopharmacol. 2011;31(1):4-9.
30. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep. 1962;10:799-812.
31. First M, Spitzer R, Gibbon M, Williams J. User's Guide for the Structured Clinical Interview for DMS-IV Axis I Disorders -Clinician Version (SCID-CV). Washington DC: American Psychiatry Press; 1997.
32. First M, Gibbon M, Spitzer R, Williams J, Benjamin L. SCID-II Personality Questionnaire. Washington DC: American Psychiatry Press; 1997.
33. Heyes M, Quearry B. Quantification of kynurenic acid in cerebrospinal fluid: effects of systemic and central L-kynurenine administration. J Chromatogr. 1990;530:108-15.
34. Josefsson M, Roman M, Skogh E, Dahl M-L. Liquid chromatography/tandem mass spectrometry method for determination of olanzapine and N-desmethylolanzapine in human serum and cerebrospinal fluid. J Pharm Biomed Anal. 2010;53(3):576-82.
35. Miller CL, Llenos IC, Dulay JR, Barillo MM, Yolken RH, Weis S. Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiol Dis. 2004;15(3):618-29.
36. Söderlund J, Schröder J, Nordin C, et al. Activation of brain interleukin-1beta in schizophrenia. Mol Psychiatry. 2009;14(12):1069-71.
37. Okuno E, Nakamura M, Schwarcz R. Two kynurenine aminotransferases in human brain. Brain Res. 1991;542(2):307-12.
38. Bender DA, McCreanor GM. Kynurenine hydroxylase: a potential rate-limiting enzyme in tryptophan metabolism. Biochem Soc Trans. 1985;13(2):441-3.
39. Holtze M, Saetre P, Engberg G, et al. Kynurenine 3-monooxygenase polymorphisms: relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls. J Psychiatry Neurosci. 2012;37(1):53-7.
40. Speciale C, Wu H, Cini M, Marconi M, Varasi M, Schwarcz R. (R,S)-3, 4-dichlorobenzoylalanine (FCE 28833 A) causes a large and persistent increase in brain kynurenic acid levels in rats. Eur J Pharmacol. 1996;315:263-7.
41. Erhardt S, Oberg H, Mathé JM, Engberg G. Pharmacological elevation of endogenous kynurenic acid levels activates nigral dopamine neurons. Amino Acids. 2001;20(4):353-62.
42. Giorgini F, Huang SY, Sathyasaikumar KV, et al. Targeted deletion of kynurenine 3-monooxygenase in mice: a new tool for studying kynurenine pathway metabolism in periphery and brain. J Biol Chem. 2013;288(51):36554-66.
43. Purcell SM, Moran JL, Fromer M, et al. A polygenic burden of rare disruptive mutations in schizophrenia. Nature. 2014;506(7487):185-90.